CareDx, Inc. (NASDAQ:CDNA) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 32.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 432,035 shares of the company's stock after purchasing an additional 104,692 shares during the period. Allspring Global Investments Holdings LLC owned 0.78% of CareDx worth $7,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Hsbc Holdings PLC boosted its position in shares of CareDx by 6.9% during the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock valued at $365,000 after buying an additional 1,109 shares during the period. Legal & General Group Plc boosted its position in shares of CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after buying an additional 1,118 shares during the period. Sterling Capital Management LLC boosted its position in shares of CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after buying an additional 1,126 shares during the period. Principal Financial Group Inc. boosted its position in shares of CareDx by 6.5% during the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after buying an additional 1,151 shares during the period. Finally, Swiss National Bank boosted its position in shares of CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock valued at $2,111,000 after buying an additional 1,800 shares during the period.

Analyst Ratings Changes

Several research firms have recently weighed in on CDNA. Stephens reaffirmed an "overweight" rating and set a $40.00 price target on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. The Goldman Sachs Group decreased their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price target on shares of CareDx in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

Insider Buying and Selling at CareDx

In related news, Director William A. Hagstrom sold 30,000 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total value of $523,500.00. Following the completion of the transaction, the director owned 53,979 shares of the company's stock, valued at $941,933.55. The trade was a 35.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christine Cournoyer sold 29,136 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the completion of the transaction, the director directly owned 37,045 shares of the company's stock, valued at $591,238.20. This trade represents a 44.02% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 129,078 shares of company stock worth $2,234,115. 4.40% of the stock is currently owned by corporate insiders.

CareDx Stock Performance

NASDAQ:CDNA traded down $0.79 during trading hours on Monday, reaching $18.45. The company's stock had a trading volume of 716,370 shares, compared to its average volume of 919,421. The company has a market capitalization of $1.03 billion, a P/E ratio of 16.04 and a beta of 2.19. CareDx, Inc. has a 12 month low of $14.09 and a 12 month high of $34.84. The stock has a 50 day moving average price of $17.79 and a two-hundred day moving average price of $19.71.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The company had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. CareDx's revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. As a group, analysts predict that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.